The 2016 World Health Organization Classification of Tumors of the Central NervousSystem(CNS) used molecular parameters in addition to histology to define manytumor entities, thus formulating a concept for how CNS tumor diagnosis should bestructured in the molecular era.IDH1 is an important molecular marker which has important clinical significance. The prognosis of gliomas with IDH1 mutation is better than those without one. In general,IDH1is detected by pathological biopsy. In this study, gliomas with or without IDH1 mutation was distinguished by using non-invasive MRI texture analysis based on 3D tumor measurement, and then the relationship between MRI texture parameters with survival rate was further assessed.
This abstract and the presentation materials are available to members only; a login is required.